Florida hospital earns HIMSS Stage 7 recognition

Florida Hospital Carrollwood, an Adventist Health System facility, has received the acute care Stage 7 award from HIMSS Analytics. The award represents attainment of the highest level on the Electronic Medical Records Adoption Model (EMRAM), which is used to track EMR progress at hospitals and health systems.

HIMSS Analytics developed the EMR Adoption Model in 2005 as a methodology for evaluating the progress and impact of electronic medical record systems for hospitals in the HIMSS Analytics Database. There are eight stages (0-7) that measure a hospital’s implementation and utilization of information technology applications. The final stage, Stage 7, represents an advanced patient record environment. The validation process to confirm a hospital has reached Stage 7 includes a site visit by an executive from HIMSS Analytics and former or current chief information officers to ensure an unbiased evaluation of the Stage 7 environments.

The hospital will be recognized at the 2014 Annual HIMSS Conference & Exhibition on Feb. 24-26, 2014, in Orlando, Fla. As of quarter 1, 2013, Florida Hospital Carrollwood, located in Tampa, is among the 106 U.S. facilities, or 1.95 percent, of the more than 5,000 U.S. hospitals in the HIMSS Analytics Database, to be awarded the HIMSS Analytics Stage 7 Award.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.